Whole-body 18F-FDG PET/CT scan in a patient with Lung Cancer taken from the PETWB-REP dataset. The following English report (translated from original Chinese) is taken verbatim from the public dataset and has not been modified or otherwise checked for accuracy (see the end for citation).

Findings

After fasting and intravenous injection of 18F-FDG, a whole-body PET/CT scan was performed.
The whole-body scan showed: The brain morphology and structure were normal; no abnormal density shadows were seen in the brain parenchyma, and FDG uptake was not significantly abnormal.
The ventricles, sulci, fissures, and cisterns were not widened; the ventricles were symmetrical, and there was no midline shift.
The eyeballs were symmetrical and without significant abnormalities.
The paranasal sinuses showed no thickening of the mucosa, and the sinus walls were intact.
The nasopharyngeal wall showed no thickening, and FDG uptake was not abnormal.
The pharyngeal recesses were symmetrical, the Eustachian tube openings were not narrowed, the infratemporal and pterygopalatine fossae were structurally normal, and the parapharyngeal spaces were clear with no abnormal FDG uptake.
The palatine tonsils showed physiological uptake.
No abnormal density shadows were seen in the parotid and submandibular glands.
The laryngopharynx was normal in morphology and structure.
The thyroid gland is normal in shape and size, with uniform density, and FDG uptake is normal.
No enlarged lymph nodes were seen in the bilateral deep cervical spaces or submandibular region.
An irregular mass measuring approximately 3.7 2.5 cm was seen in the posterior segment of the right lower lobe, with uneven density, lobulated and spiculated margins, local bronchial truncation, and adhesion to the adjacent pleura.
FDG metabolism was increased, SUVmax = 23.5, and patchy high-density shadows were seen distally.
A small ground-glass nodule measuring approximately 0.5 0.6 cm was seen in the posterior segment of the left lower lobe, with a CT value of approximately -523 HU, relatively clear borders, and apparent traction on the adjacent pleura.
FDG metabolism was normal.
Several solid micronodules were seen in both lungs, with a long diameter of approximately 0.2?.3 cm, clear borders, and FDG metabolism was normal.
A few punctate and linear lesions were also seen in both lungs, with FDG metabolism normal.
A small amount of pleural effusion was seen in the right pleural cavity.
Enlarged lymph nodes were observed in the right hilum, with a short diameter of approximately 1.5 cm.
FDG metabolism was increased, with an SUVmax of 7.5.
The cardiac silhouette was normal.
Nodular changes were observed in parts of both breasts, but FDG metabolism was normal.
The esophagus was not dilated, and the wall showed no significant thickening or mass; FDG uptake was normal.
Gastric distension was poor; the gastric wall showed no significant thickening, but some gastric wall showed increased FDG uptake (SUVmax = 2.6).
Intestinal distension was unsatisfactory; some intestinal segments showed increased FDG metabolism (SUVmax = 5.6).
The liver's shape and size were normal; the liver margins were smooth, and the hepatic fissure was not widened.
Punctate calcifications were observed in the left inner lobe of the liver; the liver parenchyma density was decreased, with a CT value of approximately 35 HU; FDG uptake was normal.
The main portal vein was not significantly widened, and no dilation was observed in the intrahepatic or extrahepatic bile ducts.
The gallbladder appears normal in shape and size, with no thickening of the gallbladder wall and no abnormal FDG uptake in the local area.
The pancreas appears normal in shape, with no obvious abnormal density shadows in the parenchyma, no widening of the main pancreatic duct, and no obvious abnormal FDG uptake.
The spleen appears normal in shape, size, density, and FDG uptake.
Both kidneys appear normal in shape and size, with no obvious abnormal density shadows in the parenchyma, no widening of the renal pelvis, calyces, or ureters, and residual contrast agent is observed.
Bilateral adrenal glands show no obvious abnormalities.
The uterus has an irregular outline, with no abnormal FDG metabolism observed.
Increased FDG uptake in the left adnexa, SUVmax=8.1.
The bladder is generally full, with residual contrast agent observed.
No enlarged lymph nodes are seen in the abdomen, pelvis, or retroperitoneal region.
A small amount of fluid is present in the pelvic cavity.
The spinal alignment is normal, and the bone structure of each vertebra is intact.
No abnormalities were observed in FDG uptake of the bones.

Impression

1. a. A mass in the posterior segment of the right lower lobe, with increased FDG metabolism, suggestive of lung cancer, accompanied by distal obstructive changes. Please confirm the diagnosis with pathological examination. Right hilar lymph node metastasis. b. Ground-glass nodule in the posterior segment of the left lower lobe, with normal FDG metabolism, likely atypical adenomatous hyperplasia. HRCT follow-up at 6-12 months is recommended to rule out other possibilities. c. Solid micronodules in both lungs, with normal FDG metabolism, likely chronic inflammatory micronodules. Please follow up with CT. Sequelae of pneumonia in both lungs. Small amount of pleural effusion on the right side. Bilateral breast hyperplasia; please follow up with ultrasound.

2. Increased FDG metabolism in parts of the stomach wall and intestines, suggestive of inflammatory or physiological uptake. Colonoscopy follow-up is recommended.

3. Liver calcifications. Fatty liver.

4. Small uterine fibroids may be large. Increased FDG metabolism in the left adnexal region is likely a physiological change; please follow up with ultrasound. Small amount of pelvic effusion.

5. Cranial FDG imaging showed no abnormalities; MRI follow-up is recommended.

This case is from PETWB-REP, a curated dataset of whole-body 18F-FDG PET/CT scans and corresponding radiology reports from 490 patients with a broad spectrum of malignancies. The data were retrospectively collected from patients who underwent clinically indicated whole-body 18F-FDG PET/CT scans at the Shanghai Universal Medical Imaging Diagnostic Center between 2021 and 2024.

License: Creative Commons Attribution 4.0 International (CC BY 4.0)

Citation:
Xue, L., Feng, G., Wenbo, Z., Zhang, Y., Li, L., Wang, S., Peng, L., Peng, S., & Gao, X. (2026). PETWB-REP: A Multi-Cancer Whole-Body FDG PET/CT Dataset with Corresponding Radiology Reports [Data set]. Zenodo. https://doi.org/10.5281/zenodo.18670487